-
1
Isavuconazole is a triazole antifungal recently registered for pediatric use, effective for invasive fungal disease in children undergoing chemotherapy or HSCT.
-
2
In a study of 55 pediatric patients, isavuconazole was primarily used for therapy (69.7%) and secondary prophylaxis (40.9%), with a median treatment duration of 76 days.
-
3
The median trough concentration (Ctrough) of isavuconazole was 3.3 mg/L, with significant variability observed, necessitating frequent dose adjustments based on drug concentrations.
-
4
Isavuconazole was well tolerated, with only 3.0% of patients experiencing grade 3 or 4 toxicity, primarily related to hepatotoxicity and electrolyte imbalances.
-
5
The study concluded that isavuconazole is suitable for pediatric patients with toxicity or drug interactions, highlighting the importance of individualized dosing.
